Literature DB >> 34767318

Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?

Peter J Neumann1, Joshua T Cohen1, Daniel A Ollendorf1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34767318     DOI: 10.1056/NEJMp2113323

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors:  Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal:  Int J Health Serv       Date:  2022-05-12       Impact factor: 1.851

2.  Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions.

Authors:  Eirik Joakim Tranvåg; Øystein Ariansen Haaland; Bjarne Robberstad; Ole Frithjof Norheim
Journal:  JAMA Netw Open       Date:  2022-06-01

3.  Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.

Authors:  Vivien Kin Yi Chan; Runqing Yang; Ian Chi Kei Wong; Xue Li
Journal:  Front Pharmacol       Date:  2022-07-11       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.